173 related articles for article (PubMed ID: 22888973)
1. Comparison of 18F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+/I- symporter in patients with untreated papillary thyroid carcinoma.
Moon SH; Oh YL; Choi JY; Baek CH; Son YI; Jeong HS; Choe YS; Lee KH; Kim BT
Endocr Res; 2013; 38(2):77-84. PubMed ID: 22888973
[TBL] [Abstract][Full Text] [Related]
2. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
3. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
4. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
[TBL] [Abstract][Full Text] [Related]
5. Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas.
Lee SJ; Choi KC; Han JP; Park YE; Choi MG
J Endocrinol Invest; 2007 Jan; 30(1):28-34. PubMed ID: 17318019
[TBL] [Abstract][Full Text] [Related]
6. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of preoperative 18F-FDG PET/CT in papillary thyroid cancer patients with a high metastatic lymph node ratio: a multicenter retrospective cohort study.
Kwon SY; Choi EK; Kong EJ; Chong A; Ha JM; Chun KA; Cho IH; Bom HS; Min JJ; Kim J; Song HC; O JH; Kim SH
Nucl Med Commun; 2017 May; 38(5):402-406. PubMed ID: 28306621
[TBL] [Abstract][Full Text] [Related]
8. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Zhang XY; Sun ZK; Luo QY
J Mol Endocrinol; 2017 Jan; 58(1):15-23. PubMed ID: 27920093
[TBL] [Abstract][Full Text] [Related]
9. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma.
Hwang SO; Lee SW; Kang JK; Choi HH; Kim WW; Park HY; Jung JH
Otolaryngol Head Neck Surg; 2014 Sep; 151(3):415-20. PubMed ID: 24903453
[TBL] [Abstract][Full Text] [Related]
11. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma.
Jung JH; Kim CY; Son SH; Kim DH; Jeong SY; Lee SW; Lee J; Ahn BC
PLoS One; 2015; 10(12):e0144152. PubMed ID: 26636824
[TBL] [Abstract][Full Text] [Related]
13. Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.
Kim SK; So Y; Chung HW; Yoo YB; Park KS; Hwang TS; Kim B; Lee WW
Cancer Med; 2016 Oct; 5(10):2756-2762. PubMed ID: 27539659
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy.
Kim BH; Lee CH; Kim SJ; Jeon YK; Kim SS; Kim YK; Kim IJ
Thyroid; 2013 Nov; 23(11):1431-6. PubMed ID: 23510334
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of integrated [18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the preoperative assessment of papillary thyroid carcinoma: comparison with sonography.
Choi WH; Chung YA; Han EJ; Sohn HS; Lee SH
J Ultrasound Med; 2011 Sep; 30(9):1267-73. PubMed ID: 21876098
[TBL] [Abstract][Full Text] [Related]
16. Axillary lymph node metastasis of papillary thyroid carcinoma detected by FDG PET/CT in a thyroglobulin-positive patient with negative whole-body 131I scan.
Elboga U; Kalender E; Yilmaz M; Celen YZ; Aktolun C
Clin Nucl Med; 2012 Nov; 37(11):1120-2. PubMed ID: 22996245
[TBL] [Abstract][Full Text] [Related]
17. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas.
Arturi F; Russo D; Giuffrida D; Schlumberger M; Filetti S
Eur J Endocrinol; 2000 Nov; 143(5):623-7. PubMed ID: 11078986
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
19. Prediction of central lymph node metastasis from papillary thyroid microcarcinoma by 18F-fluorodeoxyglucose PET/CT and ultrasonography.
Byun BH; Jeong UG; Hong SP; Min JJ; Chong A; Song HC; Bom HS
Ann Nucl Med; 2012 Jul; 26(6):471-7. PubMed ID: 22467230
[TBL] [Abstract][Full Text] [Related]
20. Correlation of BRAF mutation and SUV
Ozderya A; Temizkan S; Gul AE; Ozugur S; Sargin M; Aydin K
Endocrine; 2017 Jan; 55(1):215-222. PubMed ID: 27696232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
